CNBX Pharmaceuticals

About

CNBX Pharmaceuticals operates In Israel as G.R.I.N Ultra Ltd where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

When did CNBX Pharmaceuticals become a public company?

CNBX Pharmaceuticals went public in September 2017, trading on the OTC exchange under the ticker CNBX.

What was a significant operational change for the company in March 2022?

In March 2022, Cannabics Pharmaceuticals officially changed its name to CNBX Pharmaceuticals.

What is the status of CNBX Pharmaceuticals' patent application regarding cancer treatment with cannabinoids?

In October 2022, CNBX Pharmaceuticals' patent application titled "Composition and Method for Treating Cancer with Cannabinoids" entered the national phase in both the US and Israel.

What was a key development for CNBX Pharmaceuticals following Israel's regulatory changes in June 2020?

In June 2020, CNBX Pharmaceuticals aimed to capitalize on Israel's final approval for the export of medical cannabis.

What research findings did CNBX Pharmaceuticals announce in May 2020?

In May 2020, CNBX Pharmaceuticals announced that specific cannabis cultivars were identified to have positive anti-tumor effects on gastric adenocarcinoma.

What was the company's internal restructuring in February 2016?

In February 2016, Cannabics Pharmaceuticals placed its IP and subsidiary within the company.

Where is CNBX Pharmaceuticals headquartered?

CNBX Pharmaceuticals is headquartered in Tel Aviv-Yafo, Israel, at HaBarzel St 11.

What is the primary focus of CNBX Pharmaceuticals' platform?

CNBX Pharmaceuticals is developing a platform that uses novel drug-screening tools and artificial intelligence to create personalized cannabinoid-based cancer therapies.

CNBX Pharmaceuticals — Full Company Profile (machine-readable)

Cnnabinoid-based Cancer Therapies

About

CNBX Pharmaceuticals is developing a platform that leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based cancer therapies tailored to each patients specific profile. By developing tools to assess effectiveness on a personalized basis, Cannabics seeks to make cannabinoids part of the future of cancer therapy. CNBX Pharmaceuticals operates In Israel as G.R.I.N Ultra Ltd where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.

Facts

Name	CNBX Pharmaceuticals
Slug	cnbx-pharmaceuticals
Type	Israeli Startup
Founded	2004
HQ city	Tel Aviv-Yafo
HQ country	IL
Primary sector	[object Object]
Sectors	[object Object], [object Object], [object Object]
Business models	B2B
Status	active
Current stage	Public
Public stage	Public
Total raised (USD)	0
Website	https://cnbxpharma.com/
Israeli Companies Registrar	515125557

Public offerings (1)

Date	Kind	Exchange	Ticker	Amount	Valuation
2017-09	ipo	OTC	CNBX

Team (4)

Name	Role	LinkedIn
Eyal Barard
Eyal Ballan
Zohar Koren
Itamar Borochov

News mentions (5)

Oct 13, 2022 — www.prnewswire.com: Article
Mar 28, 2022 — www.prnewswire.com: Article
Jun 13, 2020 — www.prnewswire.com: Article
May 10, 2020 — www.prnewswire.com: Article
Feb 26, 2016 — www.prnewswire.com: Article

Intelligence Q&A

When did CNBX Pharmaceuticals become a public company?

CNBX Pharmaceuticals went public in September 2017, trading on the OTC exchange under the ticker CNBX.

What was a significant operational change for the company in March 2022?

In March 2022, Cannabics Pharmaceuticals officially changed its name to CNBX Pharmaceuticals.

What is the status of CNBX Pharmaceuticals' patent application regarding cancer treatment with cannabinoids?

In October 2022, CNBX Pharmaceuticals' patent application titled "Composition and Method for Treating Cancer with Cannabinoids" entered the national phase in both the US and Israel.

What was a key development for CNBX Pharmaceuticals following Israel's regulatory changes in June 2020?

In June 2020, CNBX Pharmaceuticals aimed to capitalize on Israel's final approval for the export of medical cannabis.

What research findings did CNBX Pharmaceuticals announce in May 2020?

In May 2020, CNBX Pharmaceuticals announced that specific cannabis cultivars were identified to have positive anti-tumor effects on gastric adenocarcinoma.

What was the company's internal restructuring in February 2016?

In February 2016, Cannabics Pharmaceuticals placed its IP and subsidiary within the company.

Where is CNBX Pharmaceuticals headquartered?

CNBX Pharmaceuticals is headquartered in Tel Aviv-Yafo, Israel, at HaBarzel St 11.

What is the primary focus of CNBX Pharmaceuticals' platform?

CNBX Pharmaceuticals is developing a platform that uses novel drug-screening tools and artificial intelligence to create personalized cannabinoid-based cancer therapies.

About

Company Intelligence Q&A

Sectors & technology

Tags